Erik Teugels
Brussels, BRU 1090, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer.
Journal: International journal of cancer
Published: July 17, 2020
Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Journal: BMC medicine
Published: February 02, 2020
The genomic landscape of nonsmall cell lung carcinoma in never smokers.
Journal: International journal of cancer
Published: March 28, 2019
The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Journal: Pathology oncology research : POR
Published: February 28, 2019
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Journal: BMC cancer
Published: August 28, 2018
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.
Journal: Oncotarget
Published: April 19, 2017
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
Journal: Journal of medical genetics
Published: January 24, 2017
Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.
Journal: Oncotarget
Published: January 18, 2017
An alternative model for (breast) cancer predisposition.
Journal: NPJ breast cancer
Published: August 19, 2016
Last Updated: 09/26/2026